PRO MEDICUS LIMITED — Interim / Quarterly Report 2012

Feb 23, 2012

Appendix 4D Half-Year Report

Rule 4.2A

==> picture [107 x 28] intentionally omitted <==

Appendix 4D Half-Year Report

1. Company details

Name of entity

1. Company details Name of entity
Pro Medicus Limited
ABN or equivalent company reference 25 006 194 752	Financial half year ended (‘current period’) 31 December 2011	Financial half year ended (‘previous period’)
25 006 194 752	31 December 2011	31 December 2010

2. Results for announcement to the market.

The information in this report should be read in conjunction with the 30 June 2011 Annual Financial Report.

Financial	Report.	Report.
ASX Listing Rules Ref			2011 A$’000
2.1	Revenue from ordinary activities As reported % change up/(down) of revenue from ordinary activities from the previous corresponding period.		7,452 Down 1.5%
2.2	Profit/(Loss) from ordinary activities after tax attributable to members % change up/(down) of Profit/(Loss) from ordinary activities after tax attributable to members from the previous corresponding period.		1,094 Up 67.5%
2.3	Net Profit/(Loss) for the period attributable to members % change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.		1,094 Up 67.5%
2.4	Dividends (distributions)	Amount per security	Franked amount per security
	Franked dividend amount per security Final Dividend Previous corresponding period Interim Dividend Previous corresponding period	— — 0.5 cents —	— — 0.5 cents —
2.5	Record date for Interim dividend 7 March 2012 Interim dividends payment dates 21 March 2012

Page 1

Appendix 4D Half-Year Report

==> picture [107 x 28] intentionally omitted <==

2.6	REVIEW AND RESULTS OF OPERATIONS The Company reported a first half after tax profit of $1.094 million, an increase of 67.5% compared to the same period last year. This was achieved on revenue of$7.452m which was largely in line with revenue from the same period in 2011. First-half profits grew as a result of higher margin sales, operational savings and positive movements in foreign currency. During this period the company continued its significant investment in R&D both in Australia as well as overseas. This has led to a number of enhancements to the existing product lines as well as significant progress with the company’s new technology RIS platform which went live at its first site in December 2011. Promedicus.net, the company's e-health offering, continued to perform well throughout the period despite increasing competition. The company’s cash reserves grew to $4.03 million at the end of December 2011, an increase of over 23%. The company continues to remain debt free. The Board is of the view that whilst difficult trading conditions in Europe and North America may provide challenges in the short to medium term, the company is now better placed to meet these challenges if and when they arise. As a result the company has announced an interim dividend of .5c per share fully franked. The company has also announced a share buyback scheme on 13thFebruary 2012 that will enable the company to buy back up to 10% of its shares over the next twelve months as part of its capital management strategy.	REVIEW AND RESULTS OF OPERATIONS The Company reported a first half after tax profit of $1.094 million, an increase of 67.5% compared to the same period last year. This was achieved on revenue of$7.452m which was largely in line with revenue from the same period in 2011. First-half profits grew as a result of higher margin sales, operational savings and positive movements in foreign currency. During this period the company continued its significant investment in R&D both in Australia as well as overseas. This has led to a number of enhancements to the existing product lines as well as significant progress with the company’s new technology RIS platform which went live at its first site in December 2011. Promedicus.net, the company's e-health offering, continued to perform well throughout the period despite increasing competition. The company’s cash reserves grew to $4.03 million at the end of December 2011, an increase of over 23%. The company continues to remain debt free. The Board is of the view that whilst difficult trading conditions in Europe and North America may provide challenges in the short to medium term, the company is now better placed to meet these challenges if and when they arise. As a result the company has announced an interim dividend of .5c per share fully franked. The company has also announced a share buyback scheme on 13thFebruary 2012 that will enable the company to buy back up to 10% of its shares over the next twelve months as part of its capital management strategy.	REVIEW AND RESULTS OF OPERATIONS The Company reported a first half after tax profit of $1.094 million, an increase of 67.5% compared to the same period last year. This was achieved on revenue of$7.452m which was largely in line with revenue from the same period in 2011. First-half profits grew as a result of higher margin sales, operational savings and positive movements in foreign currency. During this period the company continued its significant investment in R&D both in Australia as well as overseas. This has led to a number of enhancements to the existing product lines as well as significant progress with the company’s new technology RIS platform which went live at its first site in December 2011. Promedicus.net, the company's e-health offering, continued to perform well throughout the period despite increasing competition. The company’s cash reserves grew to $4.03 million at the end of December 2011, an increase of over 23%. The company continues to remain debt free. The Board is of the view that whilst difficult trading conditions in Europe and North America may provide challenges in the short to medium term, the company is now better placed to meet these challenges if and when they arise. As a result the company has announced an interim dividend of .5c per share fully franked. The company has also announced a share buyback scheme on 13thFebruary 2012 that will enable the company to buy back up to 10% of its shares over the next twelve months as part of its capital management strategy.
3.	Net Tangible Assets per security 2011 2010 Net Tangible Assets per security $0.05 $0.05
4.	Details of entities over which control has been gained or lost during the period There are no entities over which control has been gained or lost during the period.
5.	Details of Dividends
	Interim Dividend An Interim Dividend of 0.5 cents (2010: nil) per share fully franked will be paid on 21 March 2012.	2011 $’000	2010 $’000
		501	—
6.	Dividend or Distribution reinvestment plans There are no dividend or distribution reinvestment plans in operation.

Page 2

Appendix 4D Half-Year Report

==> picture [107 x 28] intentionally omitted <==

7.	Associates and joint venture entities There are no associates or relevant joint ventures.
8.	Foreign Entity accounting standards Not applicable
9.	Audit Statement This report is based on accounts to which one of the following applies. (Tick one)  The +accounts have been audited.  The+accounts have been subject to review.  The +accounts are in the process of being audited or subject to review.  The+accounts have_not_ yet been audited or reviewed.

Sign here:

==> picture [94 x 66] intentionally omitted <==

Peter T Kempen Chairman

Date: 24[th] February 2012

Page 3